FDA's CRL on hepatitis B vaccine spooks Dynavax' shares

14 November 2016
2019_biotech_test_vial_discovery_big

Shares of US clinical-stage biopharma firm Dynavax Technologies (Nasdaq: DVAX) took a 63% nosedive in Monday morning’s trading after bad news on its hepatitis B vaccine.

Chief executive Eddie Gray admitted that the company might not be able to advance Heplisav-B (hepatitis B vaccine, recombinant (adjuvanted)) alone and quickly needed to find a partner to continue the program, after the receipt of a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA).

The CRL, relating to Dynavax’s Biologics License Application for Heplisav-B, seeks information regarding several topics, including clarification regarding specific adverse events of special interest (AESIs).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology